drugset / Trial / NCT05218434

A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

NCT05218434 ↗

Phase 1 Completed 64 enrolled Artax Biopharma Inc Simbec-Orion Group · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase I Healthy volunteer study with the primary objective to evaluate the safety and pharmacokinetics profile of AX-158. The first part will evaluate single ascending dose administrations. A substudy will be performed as well to evaluate possible impact of food on drug exposure if administered under fasted or fed state. The second part will evaluate multiple ascending dose over 10 days of dosing in fed or fast state depending on the results of the substudy food effect on AX-158.

Timeline

Start
2021-11-17
Primary completion
2022-11-16
Completion
2022-12-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AX-158 Unknown 5 mg Oral
Subject AX-158 Unknown 10 mg Oral
Subject AX-158 Unknown 15 mg Oral
Subject AX-158 Unknown 25 mg Oral
Subject AX-158 Unknown 50 mg Oral

Indications